DK1771450T3 - Forbindelser og fremgangsmåder til inhibering af mitotisk progression ved inhibering af AURORA-kinase - Google Patents

Forbindelser og fremgangsmåder til inhibering af mitotisk progression ved inhibering af AURORA-kinase

Info

Publication number
DK1771450T3
DK1771450T3 DK05779921T DK05779921T DK1771450T3 DK 1771450 T3 DK1771450 T3 DK 1771450T3 DK 05779921 T DK05779921 T DK 05779921T DK 05779921 T DK05779921 T DK 05779921T DK 1771450 T3 DK1771450 T3 DK 1771450T3
Authority
DK
Denmark
Prior art keywords
inhibition
compounds
methods
aurora kinase
mitotic progression
Prior art date
Application number
DK05779921T
Other languages
English (en)
Other versions
DK1771450T5 (da
Inventor
Christopher F Claiborne
Lloyd J Payne
Richard J Boyce
Todd B Sells
Stephen G Stroud
Stuart Travers
Tricia J Vos
Gabriel S Weatherhead
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of DK1771450T3 publication Critical patent/DK1771450T3/da
Publication of DK1771450T5 publication Critical patent/DK1771450T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Small-Scale Networks (AREA)
DK05779921.5T 2004-05-14 2005-05-12 Forbindelser og fremgangsmåder til inhibering af mitotisk progression ved inhibering af AURORA-kinase DK1771450T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57165304P 2004-05-14 2004-05-14
US61722104P 2004-10-08 2004-10-08
PCT/US2005/016445 WO2005111039A2 (en) 2004-05-14 2005-05-12 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Publications (2)

Publication Number Publication Date
DK1771450T3 true DK1771450T3 (da) 2008-04-28
DK1771450T5 DK1771450T5 (da) 2012-01-09

Family

ID=35262144

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05779921.5T DK1771450T5 (da) 2004-05-14 2005-05-12 Forbindelser og fremgangsmåder til inhibering af mitotisk progression ved inhibering af AURORA-kinase

Country Status (26)

Country Link
US (9) US7572784B2 (da)
EP (4) EP2746285B1 (da)
JP (4) JP4467616B2 (da)
KR (3) KR20120091275A (da)
CN (1) CN104193750B (da)
AR (1) AR049277A1 (da)
AT (1) ATE381566T1 (da)
AU (1) AU2005243175B2 (da)
BR (1) BRPI0511139B8 (da)
CA (1) CA2565411C (da)
CY (2) CY1108092T1 (da)
DE (1) DE602005003951T4 (da)
DK (1) DK1771450T5 (da)
EA (1) EA012112B1 (da)
ES (3) ES2540987T3 (da)
HK (4) HK1102500A1 (da)
HR (2) HRP20080120T5 (da)
IL (1) IL179063A (da)
MX (1) MXPA06013042A (da)
MY (1) MY139355A (da)
NZ (1) NZ551370A (da)
PL (1) PL1771450T3 (da)
PT (2) PT1771450E (da)
RS (2) RS52436B (da)
TW (1) TWI338688B (da)
WO (1) WO2005111039A2 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565411C (en) * 2004-05-14 2010-04-20 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
CN101068815B (zh) * 2004-10-04 2012-09-05 千禧药品公司 有效作为蛋白激酶抑制剂的内酰胺化合物
WO2006046735A1 (en) * 2004-10-29 2006-05-04 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
EP1876178B1 (en) 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
MX2007013257A (es) * 2005-05-05 2008-01-21 Chroma Therapeutics Ltd Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa.
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
EP1978964A4 (en) * 2006-01-24 2009-12-09 Merck & Co Inc JAK2 tyrosine kinase Inhibition
JP2009530274A (ja) * 2006-03-15 2009-08-27 ワイス ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物
JP2009530342A (ja) * 2006-03-20 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法
ATE533744T1 (de) * 2006-05-19 2011-12-15 Wyeth Llc N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AU2012203952B2 (en) * 2006-11-16 2014-12-11 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AU2014280932B2 (en) * 2006-11-16 2016-10-06 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
AR066721A1 (es) * 2007-05-24 2009-09-09 Wyeth Corp Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso.
TW200914457A (en) 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
US7803825B2 (en) * 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
BRPI0816320A2 (pt) * 2007-09-04 2015-03-24 Biolipox Ab Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
JP2010539180A (ja) * 2007-09-12 2010-12-16 ワイス・エルエルシー ヒスタミン３拮抗薬としてのイソキノリニルおよびイソインドリニル誘導体
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
JP2009108036A (ja) * 2007-09-28 2009-05-21 Fujifilm Corp 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物
JP5555186B2 (ja) * 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
EP2276346B1 (en) 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
US20110112193A1 (en) * 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
JP5684719B2 (ja) 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
MX2011006725A (es) * 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
CA2754946A1 (en) 2009-03-12 2010-09-16 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
CA2754941A1 (en) 2009-03-12 2010-09-16 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
EP2406219A1 (en) 2009-03-12 2012-01-18 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
CN102341371A (zh) 2009-03-12 2012-02-01 比奥里波克斯公司 用作ltc4合酶抑制剂的双芳族化合物
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
EP2545036A1 (en) 2010-03-12 2013-01-16 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103804391A (zh) * 2012-11-01 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020130125A1 (ja) 2018-12-21 2020-06-25 第一三共株式会社 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN112062768B (zh) * 2020-07-20 2021-08-31 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 具有Aurora激酶降解活性的小分子及其制备方法和应用
CA3239690A1 (en) * 2021-12-14 2023-06-22 Prazer Therapeutics Inc. Novel compound for degrading target protein or polypeptide by using polyubiquitination

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947585A (en) * 1974-06-03 1976-03-30 Ciba-Geigy Corporation Pyrazolobenzazepines
US4022801A (en) 1974-06-03 1977-05-10 Ciba-Geigy Corporation Pyrazolobenzazepines
US4028381A (en) 1975-05-05 1977-06-07 Ciba-Geigy Corporation Pyrazolobenzazepines
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
KR840000062B1 (ko) 1979-02-07 1984-01-31 에프. 호프만-라롯슈 앤드 캄파니 아크티엔게젤샤프트 벤즈아제핀 유도체의 제조방법
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4318854A (en) 1979-02-07 1982-03-09 Hoffmann-La Roche Inc. Intermediates in the production of 2-benzazepines
US4547581A (en) 1979-02-07 1985-10-15 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines and intermediates in their preparation
ZA80492B (en) * 1979-02-07 1981-01-28 Hoffmann La Roche Benzazepine derivatives
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
NL8102182A (nl) 1981-05-04 1982-12-01 Philips Nv Kleurenbeeldbuis.
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
CN1084747C (zh) 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
WO1999016770A1 (fr) 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Derives de triazolobenzazepine tricyclique, leur procede de production et antiallergique
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE60120198T2 (de) * 2000-09-15 2007-05-10 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
US6653301B2 (en) * 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2565411C (en) * 2004-05-14 2010-04-20 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
AU2005306458B2 (en) 2004-11-17 2011-02-17 Miikana Therapeutics, Inc. Kinase inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري

Also Published As

Publication number Publication date
US7572784B2 (en) 2009-08-11
EP2719698A1 (en) 2014-04-16
CA2565411A1 (en) 2005-11-24
EP1771450B9 (en) 2008-12-24
US9102678B2 (en) 2015-08-11
CN104193750B (zh) 2018-04-27
EP1771450A2 (en) 2007-04-11
EP2261226B1 (en) 2015-04-01
AR049277A1 (es) 2006-07-12
DK1771450T5 (da) 2012-01-09
KR101748290B1 (ko) 2017-06-16
IL179063A (en) 2016-05-31
PT1905773E (pt) 2012-10-25
EP2719698B1 (en) 2016-10-05
KR20130073993A (ko) 2013-07-03
US20240083906A1 (en) 2024-03-14
PL1771450T3 (pl) 2008-05-30
TWI338688B (en) 2011-03-11
AU2005243175A1 (en) 2005-11-24
BRPI0511139A (pt) 2007-11-27
RS50568B8 (sr) 2019-08-30
RS50568B (sr) 2010-05-07
ES2540987T3 (es) 2015-07-15
HK1205102A1 (en) 2015-12-11
EA200602100A1 (ru) 2007-04-27
US11014928B2 (en) 2021-05-25
US20200247810A1 (en) 2020-08-06
KR20120091275A (ko) 2012-08-17
JP4467616B2 (ja) 2010-05-26
MXPA06013042A (es) 2007-02-12
HK1114853A1 (en) 2008-11-14
EP1771450B1 (en) 2007-12-19
DE602005003951T2 (de) 2008-12-11
DE602005003951T4 (de) 2012-10-11
US20070185087A1 (en) 2007-08-09
US8399659B2 (en) 2013-03-19
US20090299060A1 (en) 2009-12-03
HRP20080120T3 (en) 2008-04-30
US10414770B2 (en) 2019-09-17
ES2299080T3 (es) 2008-05-16
BRPI0511139B1 (pt) 2019-05-21
US9765078B2 (en) 2017-09-19
WO2005111039A3 (en) 2006-04-20
JP2012006972A (ja) 2012-01-12
HRP20120785T1 (hr) 2012-11-30
JP2014114319A (ja) 2014-06-26
RS50568B9 (sr) 2019-06-28
US20220041605A1 (en) 2022-02-10
EA012112B1 (ru) 2009-08-28
EP2261226A1 (en) 2010-12-15
US20050256102A1 (en) 2005-11-17
US20140046055A1 (en) 2014-02-13
BRPI0511139B8 (pt) 2021-05-25
JP2008285484A (ja) 2008-11-27
EP2746285A1 (en) 2014-06-25
ATE381566T1 (de) 2008-01-15
PT1771450E (pt) 2008-03-31
ES2391577T3 (es) 2012-11-27
US20180134716A1 (en) 2018-05-17
EP2746285B1 (en) 2016-09-14
HK1199254A1 (en) 2015-06-26
US20160185782A1 (en) 2016-06-30
NZ551370A (en) 2009-08-28
CA2565411C (en) 2010-04-20
JP5148358B2 (ja) 2013-02-20
JP2007537268A (ja) 2007-12-20
CN104193750A (zh) 2014-12-10
AU2005243175B2 (en) 2011-12-01
CY1113192T1 (el) 2016-04-13
CY1108092T1 (el) 2014-02-12
WO2005111039A2 (en) 2005-11-24
HRP20080120T5 (hr) 2012-07-31
MY139355A (en) 2009-09-30
KR20070011606A (ko) 2007-01-24
IL179063A0 (en) 2007-03-08
HK1102500A1 (en) 2007-11-23
RS52436B (en) 2013-02-28
KR101792651B1 (ko) 2017-11-20
DE602005003951D1 (de) 2008-01-31
TW200604192A (en) 2006-02-01
JP5827708B2 (ja) 2015-12-02

Similar Documents

Publication Publication Date Title
DK1771450T5 (da) Forbindelser og fremgangsmåder til inhibering af mitotisk progression ved inhibering af AURORA-kinase
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
IL178967A0 (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
ME00716B (me) Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
EP1962830A4 (en) AZAINDOL HEMMER OF AURORA KINASES
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DK1959981T3 (da) Anti-connexin 43 forbindelser til behandling af kroniske sår
DK1720802T3 (da) Okidation af organiske forbindelser ved højt pH
EP2121637A4 (en) ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
DK3342425T3 (da) Modificerede oligonukleotider til inhibering af telomerase
DK2086981T3 (da) Forbindelser til inhibering af mitoseprogression
DK2848610T3 (da) Hæmmere af kinaseaktivitet
EP1957078A4 (en) PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER BY INHIBITING AURORA KINASE
EP1807077A4 (en) INHIBITORS OF C-FMS KINASE
GB0608823D0 (en) Inhibitors of P13 kinase
DK1723085T3 (da) Fremgangsmåde til afvanding af kloakslam
EP1851213A4 (en) INHIBITORS OF MITOTIC KINESINE
DK1786799T3 (da) Hidtil ukendte phenylaminopyrimidinderivater som inhibitorer af bcr-abl-kinase
ZA200809874B (en) Method of inhibiting c kit kinase
DK1817387T3 (da) Anvendelse af polysilazaner til belægning af metalbånd
DK1713805T3 (da) Kinaseinhibitorer
SI1905773T1 (sl) Spojine in postopki za inhibiranje mitotične progresije z inhibiranjem aurora kinaze
EP1697331A4 (en) INHIBITORS OF MITOTIC KINESINE
EP1784181A4 (en) VEGF Inhibition